Understanding the Shift: Marijuana’s Move from Schedule I to Schedule III
On December 18 2025, President Donald Trump signed an Executive Order that directs the Department of Justice to re‑classify marijuana under the Controlled Substances Act (CSA) from Schedule I to Schedule III. This action marks the first time in over fifty years that the federal government formally acknowledges the plant’s accepted medical use and its relatively low potential for dependence. While the change does not legalize marijuana nationwide, it removes several long‑standing barriers that have hindered cannabis businesses, researchers, and patients.
What Does Schedule III Mean?
Under the CSA, substances are placed into five schedules based on two criteria: potential for abuse and currently accepted medical use in the United States. Schedule III drugs are recognized as having an accepted medical application and a moderate‑to‑low risk of physical or psychological dependence. Examples include certain anabolic steroids, ketamine, and combination products containing less than 15 milligrams of hydrocodone per dosage unit.
By contrast, Schedule I substances—such as heroin, LSD, and ecstasy—are deemed to have no accepted medical use and a high abuse potential. Marijuana has remained in Schedule I since the CSA’s enactment in 1970, despite a growing body of evidence supporting its therapeutic value for conditions like chronic pain, epilepsy, and multiple sclerosis.
Key Directives of the Executive Order
The order outlines specific actions for several federal agencies, aiming to complete the rescheduling process as quickly as permissible under existing law.
Attorney General
The Attorney General is instructed to take all necessary steps to finalize the rulemaking that moves marijuana to Schedule III, employing the most expeditious route allowed by 21 U.S.C. § 811.
White House Legislative and Political Affairs
The Assistant to the President and Deputy Chief of Staff for Legislative, Political, and Public Affairs must work with Congress to update the statutory definition of hemp‑derived cannabinoid products. The goal is to preserve access to full‑spectrum CBD while imposing THC limits per serving and container, and establishing CBD‑to‑THC ratio standards that address the restrictive 0.4 mg per‑container cap introduced by Public Law 119‑37.
Health and Human Services Agencies
HHS, the FDA, CMS, and the NIH are tasked with developing research models that rely on real‑world evidence to improve patient access to hemp‑derived cannabinoids and to inform clinical standards of care. This includes exploring a Medicare pilot program that would test CBD treatments for seniors.
Pathways to Rescheduling
The Order highlights two procedural routes the Attorney General may pursue.
Option One: The Treaty Exception (“Epidiolex Method”)
Section 811(d)(1) of the CSA allows the Attorney General to issue a Final Order when control of a substance is required to meet international treaty obligations. By relying on an Office of Legal Counsel opinion that the United States can satisfy its treaty commitments by placing marijuana in Schedule III—provided that appropriate production quotas and import/export permits are in place—the DOJ could bypass the usual administrative hearing process and issue a rescheduling order immediately.
Option Two: Standard Notice‑and‑Comment Rulemaking
If the treaty route is not used, the Attorney General may follow the conventional rulemaking path under 21 U.S.C. § 811, which involves a public notice, a comment period (potentially as short as 30 days), administrative hearings, and the issuance of a final rule. This approach was previously stalled during the Biden administration due to procedural challenges and allegations of bias.
Impact on Hemp‑Derived Cannabinoid Products
The Executive Order also addresses the growing tension between federal hemp policy and state‑level cannabis markets. Recent legislation (Public Law 119‑37) imposed a strict 0.4 mg THC limit per container, threatening to reclassify many full‑spectrum CBD products as controlled substances. The order calls for a revised regulatory framework that:
- Sets THC limits per serving and per container;
- Establishes CBD‑to‑THC ratio requirements;
- Presents a clear pathway for legitimate, full‑spectrum CBD products to remain accessible;
- Directs HHS, FDA, CMS, and NIH to develop evidence‑based research models to guide best practices.
These measures aim to protect consumers from inadvertently high‑THC products while ensuring that patients and manufacturers retain access to therapeutically valuable cannabinoid profiles.
Immediate Benefits of Moving to Schedule III
Although federal prohibition remains, the rescheduling delivers several concrete advantages for the cannabis industry and its stakeholders.
Taxation Relief
One of the most immediate effects is the removal of Internal Revenue Code Section 280E, which currently forbids cannabis businesses from deducting ordinary expenses. Schedule III status eliminates this penalty, allowing companies to claim standard business deductions, thereby improving profitability and freeing capital for reinvestment, hiring, and research.
Banking and Finance
While rescheduling does not grant blanket access to traditional banking, it reduces the perceived legal risk for financial institutions. This shift may encourage more banks and credit unions to offer services such as loans and merchant accounts to licensed operators, enhancing the industry’s financial stability. A more favorable banking environment also increases the likelihood of congressional support for measures like the SAFER Banking Act and the CLIMB Act.
Medical Research
Schedule III classification acknowledges cannabis’s accepted medical use, which can help diminish stigma within academic and medical institutions. Researchers will still need to obtain material through DEA‑registered manufacturers, but the broader pool of registered suppliers and a streamlined registration process could facilitate more robust clinical trials. This, in turn, may lead to stronger efficacy and safety data, supporting future FDA approvals of standardized cannabis‑derived medications.
Prescription Pathways
Under the current framework, only FDA‑approved cannabinoid medicines (e.g., Epidiolex, Marinol, Syndros) may be prescribed by DEA‑registered practitioners and dispensed by pharmacies. Rescheduling does not alter the requirement that a drug undergo the New Drug Application process to be marketed interstate. However, by lowering the regulatory burden associated with Schedule I research, the change may incentivize pharmaceutical companies to pursue FDA approval for new, standardized cannabinoid formulations.
Looking Ahead: What Rescheduling Does—and Does Not—Change
It is crucial to understand that moving marijuana to Schedule III does not:
- Legalize marijuana at the federal level;
- Automatically bring state‑licensed dispensaries into compliance with the CSA or the Federal Food, Drug, and Cosmetic Act;
- Convert state‑issued “recommendations” into valid federal prescriptions;
- Eliminate all criminal penalties related to marijuana trafficking (mandatory minimum sentences based on quantity remain largely unchanged).
What it does achieve is a formal federal acknowledgment of cannabis’s therapeutic value and a reduction in the fiscal and operational burdens that have long hindered the industry. This acknowledgment creates momentum for further reforms, including potential congressional action to address the enduring federal‑state conflict, improve access to banking, and establish a coherent, evidence‑based framework for both marijuana and hemp‑derived products.
Conclusion
The December 2025 Executive Order represents a watershed moment in U.S. drug policy. By directing the rescheduling of marijuana to Schedule III, the administration bridges a gap between federal law, scientific evidence, and public opinion. While significant work remains to fully reconcile federal prohibition with state‑legal cannabis markets, the immediate relief from Section 280E, the potential for improved banking relationships, and the renewed impetus for medical research collectively signal a promising step toward a more rational and evidence‑based approach to cannabis regulation in the United States.
For a deeper dive into the legal and business implications of Schedule III and the federal‑state pilot program, check out our catalogue of resources: Here.
